Eris Lifesciences Limited
NSE: ERIS BSE: ERIS
NSE
1,420.60
37.20 (2.69%)
Prev Close
1383.4
Open Price
1425
Volume
40,260
Today Low / High
1391.6 / 1438.9
52 WK Low / High
1097.2 / 1910
Range
1,350 - 1,492
BSE
1,420.00
37.70 (2.73%)
Prev Close
1382.3
Open Price
1387.95
Volume
528
Today Low / High
1387.95 / 1420
52 WK Low / High
1140 / 1909.55
Range
1,349 - 1,491
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1420.6 (target range: 1,350 - 1,492), reflecting a change of 37.2 (2.68903%). On the BSE, it is listed at 1420 (target range: 1,349 - 1,491), showing a change of 37.7 (2.72734%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
02 Feb
1,375.00
0.61%
01 Feb
1,374.50
0.79%
30 Jan
1,330.00
3.42%
29 Jan
1,350.90
-0.64%
28 Jan
1,343.20
0.57%
27 Jan
1,380.00
-2.67%
23 Jan
1,444.00
-4.04%
22 Jan
1,372.50
3.37%
21 Jan
1,394.50
-0.71%
20 Jan
1,434.90
-3.66%
19 Jan
1,447.00
-0.21%
16 Jan
1,470.00
-1.16%
14 Jan
1,477.10
-0.22%
13 Jan
1,506.70
-1.96%
12 Jan
1,496.00
-0.11%
09 Jan
1,542.50
-2.18%
08 Jan
1,553.90
-1.25%
07 Jan
1,550.00
0.25%
06 Jan
1,550.00
0.13%
Eris Lifesciences Limited Graph
Eris Lifesciences Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Eris Lifesciences Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,420.60, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,420.00 | 1,434.20 | 1,290.78 - 1,577.62 |
| 1,448.40 | 1,158.72 - 1,738.08 | ||
| 1,462.60 | 1,023.82 - 1,901.38 | ||
| Bearish Scenario | 1,420.00 | 1,405.80 | 1,265.22 - 1,546.38 |
| 1,391.60 | 1,113.28 - 1,669.92 | ||
| 1,377.40 | 964.18 - 1,790.62 |
Overview of Eris Lifesciences Limited
ISIN
INE406M01024
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
133,326
Market Cap
193,931,987,717
Last Dividend
7.35
Official Website
IPO Date
2017-06-30
DCF Diff
-3,669.92
DCF
5,518
Financial Ratios Every Investor Needs
Stock Dividend of ERIS
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-02-13 | February 13, 25 | 7.35 | 7.35 | 2025-02-13 | 2025-03-09 | |
| 2022-08-11 | August 11, 22 | 7.35 | 7.35 | 2022-08-16 | 2022-09-04 | |
| 2021-08-05 | August 05, 21 | 6.01 | 6.01 | 2021-08-06 | 2021-08-28 | |
| 2020-08-13 | August 13, 20 | 5.5 | 5.5 | 2020-08-14 | 2020-09-03 | 2020-08-04 |
| 2020-03-19 | March 19, 20 | 2.87 | 2.87 | 2020-03-20 | 2020-04-10 | 2020-03-05 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 2,879.26 Cr | 730.10 Cr | 2,149.16 Cr | 0.7464 | 2.44 Cr | 508.04 Cr | 1,660.18 Cr | 351.84 Cr | 25.85 | 1,017.20 Cr | 0.1222 |
| 2024-03-31 | 1,991.30 Cr | 996.68 Cr | 994.62 Cr | 0.4995 | 5.72 Cr | 71.48 Cr | 495.30 Cr | 391.98 Cr | 28.82 | 698.65 Cr | 0.1968 |
| 2023-03-31 | 1,661.82 Cr | 352.35 Cr | 1,309.47 Cr | 0.7880 | 6.10 Cr | 47.18 Cr | 429.48 Cr | 382.16 Cr | 28.10 | 548.08 Cr | 0.2300 |
| 2022-03-31 | 1,326.17 Cr | 260.81 Cr | 1,065.36 Cr | 0.8033 | 32.74 Cr | 50.41 Cr | 431.36 Cr | 406.11 Cr | 29.89 | 511.12 Cr | 0.3062 |
| 2021-03-31 | 1,192.64 Cr | 241.87 Cr | 950.78 Cr | 0.7972 | 5.09 Cr | 43.04 Cr | 396.17 Cr | 355.14 Cr | 26.16 | 439.46 Cr | 0.2978 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 222.83 Cr | 7,033.17 Cr | 3,761.41 Cr | 2,854.3600 Cr | 2,477.92 Cr | 2,255.09 Cr | 334.83 Cr | 662.07 Cr | 0.00 Cr | 4.47 Cr | 62.00 Cr | 1,381.3900 Cr |
| 2024-03-31 | 94.14 Cr | 7,048.84 Cr | 3,826.81 Cr | 2,586.1190 Cr | 2,781.27 Cr | 2,687.13 Cr | 189.03 Cr | 534.17 Cr | 20.93 Cr | 1.38 Cr | 15.73 Cr | 2,532.0770 Cr |
| 2023-03-31 | 56.02 Cr | 3,667.33 Cr | 1,446.65 Cr | 2,195.9880 Cr | 876.71 Cr | 820.69 Cr | 131.44 Cr | 377.38 Cr | 103.45 Cr | 8.74 Cr | 6.88 Cr | 443.2330 Cr |
| 2022-03-31 | 50.79 Cr | 2,272.14 Cr | 363.94 Cr | 1,908.3110 Cr | 84.41 Cr | 33.61 Cr | 117.91 Cr | 191.86 Cr | 62.62 Cr | 5.69 Cr | 423.66 Cr | 199.6460 Cr |
| 2021-03-31 | 36.87 Cr | 1,834.78 Cr | 258.36 Cr | 1,576.4210 Cr | 6.78 Cr | -30.09 Cr | 94.47 Cr | 77.88 Cr | 48.74 Cr | 6.11 Cr | 228.25 Cr | 166.9310 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,065.0100 Cr | -79.9700 Cr | -881.3200 Cr | 910.0100 Cr | 105.4950 Cr | 199.7400 Cr | -155.0000 Cr | 351.8400 Cr | -397.2100 Cr | -100.0500 Cr | -94.3600 Cr |
| 2024-03-31 | 486.0050 Cr | -1,854.5220 Cr | 1,379.7790 Cr | 356.8430 Cr | 38.2230 Cr | 94.2450 Cr | -129.1630 Cr | 391.9830 Cr | 1,463.6990 Cr | 0.0000 Cr | -16.9400 Cr |
| 2023-03-31 | 291.7380 Cr | -982.1010 Cr | 688.0250 Cr | -549.6830 Cr | 5.1520 Cr | 56.0220 Cr | -841.4210 Cr | 404.6430 Cr | 817.8000 Cr | -99.9110 Cr | 4.7440 Cr |
| 2022-03-31 | 378.2640 Cr | -319.6100 Cr | -44.6990 Cr | 257.2310 Cr | 13.9550 Cr | 50.8700 Cr | -121.0330 Cr | 442.1980 Cr | 33.5000 Cr | -81.6230 Cr | -23.4450 Cr |
| 2021-03-31 | 375.3610 Cr | -323.3580 Cr | -82.3950 Cr | 349.5980 Cr | -30.3920 Cr | 36.9150 Cr | -25.7630 Cr | 394.4970 Cr | 0.0100 Cr | -74.6790 Cr | -24.9910 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 790.15 Cr | 202.41 Cr | 587.74 Cr | 0.7438 | 219.13 Cr | 120.19 Cr | 8.82 | 291.30 Cr | 0.1521 |
| 2025-06-30 | 771.56 Cr | 184.64 Cr | 586.92 Cr | 0.7607 | 206.20 Cr | 117.99 Cr | 8.66 | 280.29 Cr | 0.1529 |
| 2025-03-31 | 702.60 Cr | 170.25 Cr | 532.35 Cr | 0.7577 | 410.90 Cr | 93.84 Cr | 6.90 | 254.01 Cr | 0.1336 |
| 2024-12-31 | 722.12 Cr | 176.88 Cr | 545.24 Cr | 0.7551 | 169.11 Cr | 83.63 Cr | 6.15 | 254.53 Cr | 0.1158 |
| 2024-09-30 | 741.17 Cr | 392.38 Cr | 348.79 Cr | 0.4706 | 184.03 Cr | 91.59 Cr | 6.73 | 269.06 Cr | 0.1236 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 56.06 Cr | 27.86 Cr | 83.92 Cr | 651.01 Cr | 408.68 Cr | 1,391.16 Cr | 798.46 Cr | 7,159.96 Cr | 3,656.48 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 205.47 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -3,271.76 Cr |
| 2025-03-31 | 222.83 Cr | 5.00 Cr | 227.83 Cr | 458.64 Cr | 334.83 Cr | 1,222.99 Cr | 662.07 Cr | 7,033.17 Cr | 3,761.41 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 242.55 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -3,177.15 Cr |
| 2024-09-30 | 206.52 Cr | 36.03 Cr | 242.55 Cr | 567.50 Cr | 256.28 Cr | 1,317.66 Cr | 520.44 Cr | 7,021.88 Cr | 3,844.73 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 117.99 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 93.84 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 83.63 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 91.59 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 83.18 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,682.70 | ₹4,037,360,954,019.00 | ₹2,175,122.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,244.50 | ₹1,657,718,547,810.00 | ₹98,152.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,042.00 | ₹1,367,996,468,480.00 | ₹159,874.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,224.00 | ₹1,019,063,464,560.00 | ₹528,921.00 |
| Lupin Limited | LUPIN | ₹2,169.00 | ₹990,797,031,000.00 | ₹204,948.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹900.35 | ₹905,962,772,897.00 | ₹271,538.00 |
| Mankind Pharma Limited | MANKIND | ₹2,122.90 | ₹876,343,887,349.00 | ₹63,792.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,230.40 | ₹714,618,316,939.00 | ₹978,482.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,667.50 | ₹677,634,637,500.00 | ₹34,484.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,964.00 | ₹554,242,388,876.00 | ₹162,495.00 |
| Laurus Labs Limited | LAURUSLABS | ₹981.65 | ₹529,950,213,720.00 | ₹735,288.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,450.20 | ₹367,921,856,944.00 | ₹22,979.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,793.20 | ₹348,970,184,957.00 | ₹14,592.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,896.40 | ₹304,248,934,000.00 | ₹55,916.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,514.10 | ₹287,031,782,814.00 | ₹46,641.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,359.00 | ₹220,826,857,671.00 | ₹314,141.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,670.50 | ₹216,762,500,000.00 | ₹3,564.00 |
| Eris Lifesciences Limited | ERIS | ₹1,423.60 | ₹193,918,366,028.00 | ₹40,260.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,510.00 | ₹173,331,800,390.00 | ₹33,838.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹989.10 | ₹156,643,517,747.00 | ₹39,283.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹789.85 | ₹155,255,383,491.00 | ₹36,998.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹848.30 | ₹151,938,902,721.00 | ₹280,562.00 |
| Cohance Lifesciences Limited | COHANCE | ₹384.50 | ₹147,097,065,330.00 | ₹110,639.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,841.60 | ₹139,983,139,354.00 | ₹33,193.00 |
| Granules India Limited | GRANULES | ₹567.25 | ₹137,653,829,151.00 | ₹190,121.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹946.40 | ₹116,157,350,400.00 | ₹28,498.00 |
| Viyash Scientific Limited | VIYASH | ₹214.98 | ₹93,775,471,074.00 | ₹766,380.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,247.00 | ₹87,096,957,354.00 | ₹9,080.00 |
| Strides Pharma Science Limited | STAR | ₹852.40 | ₹78,568,023,257.00 | ₹112,827.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹785.50 | ₹71,203,449,437.00 | ₹51,323.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹445.80 | ₹68,252,897,456.00 | ₹28,558.00 |
| FDC Limited | FDC | ₹380.50 | ₹61,949,236,962.00 | ₹42,113.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹297.35 | ₹58,156,252,988.00 | ₹194,189.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹139.17 | ₹45,163,669,402.00 | ₹1,180,523.00 |
| Innova Captab Limited | INNOVACAP | ₹728.45 | ₹41,685,499,530.00 | ₹27,907.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹397.55 | ₹36,284,388,500.00 | ₹90,829.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹325.30 | ₹35,446,400,705.00 | ₹46,236.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹674.65 | ₹34,217,644,188.00 | ₹24,730.00 |
| Suven Life Sciences Limited | SUVEN | ₹142.85 | ₹32,494,660,900.00 | ₹92,987.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,963.50 | ₹32,474,355,953.00 | ₹9,519.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹302.00 | ₹30,285,316,812.00 | ₹34,224.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹396.05 | ₹27,884,197,288.00 | ₹19,688.00 |
Key Executives
Chairman & MD
Amit Indubhushan Bakshi
Gender: male
Year Born: 1975
Senior Vice President
Deepak Kapoor
Gender: male
Year Born: 1964
President of Sales & Marketing
Gagan Atreja
Gender: male
Year Born: 1969
Executive Director
Inderjeet Singh Negi
Gender: male
Year Born: 1971
Whole Time Director
Kaushal Kamlesh Shah
Gender: male
Year Born: 1979
Executive Director & Chief Operating Officer
Krishnakumar Vaidyanathan
Gender: male
Year Born: 1975
Compliance Officer & Company Secretary
Milind Talegaonkar
Gender: male
Year Born:
President of Cardiometabolic Business
Murari Ranganathan
Gender: male
Year Born:
Chief Financial Officer
Sachin Shah
Gender: male
Year Born: 1980
President of Medical
Vijay S. Joshi
Gender: male
Year Born: 1953
FAQs about Eris Lifesciences Limited
Who is the CEO of the company?
The CEO is Amit Indubhushan Bakshi.
What is the current market price of the stock?
The current price is ₹1,423.70.
What is the 52-week price range?
The range is ₹1097.2-1910.
What is the market capitalization of the company?
The market capitalization is ₹19,393.20 crores.
What is the dividend yield?
The dividend yield is 0.52%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 46.68.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Eris Lifesciences Limited (ISIN: INE406M01024) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹19,393.20 crores and an average daily volume of 133,326 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹7.35.